Sulphasalazine therapy in RA SIR, Pullar et al reported recently the effect of acetylator phenotype on the efficacy of sulphasalazine therapy in rheumatoid arthritis (RA). ' We would largely agree with their conclusion that there is little practical value in determining acetylator phenotype before therapy2 but would like to comment on the incidence of slow and fast acetylator phenotypes in RA and the suggestion that fast acetylators may be subject to more severe disease.
During the course of investigations on the use of sulphasalazine in RA we have phenotyped 108 patients using a modification of Schroder's method.3 Thirty three patients (30.6%) were male and 80 (74l1%) were seropositive. Sixty two (57.4%) of our patients were slow acetylators, a figure which is in agreement with the reported incidence in the general UK population4 and other studies of RA patients.h
It is always dangerous to decide what is serious or mild disease at a single point in the evolution of a chronic relapsing disorder, but all of our patients were felt to have disease of sufficient severity to warrant second line therapy, and the mean erythrocyte sedimentation rates (mm/lst h) at the start of treatment with sulphasalazine were 50 2 (SD 29.4) in the slow acetylators and 51 7 (SD 24.5) in the fast. There is no statistical difference between these figures.
We would conclude therefore that the distribution of acetylator phenotype in patients with RA is the same as that in the general population and that acetylator phenotype has no bearing on the severity of RA. 
